Big Pharma Leverages the Power of AI in Drug Development

Big Pharma Leverages the Power of AI in Drug Development

In 2018, 61 new drugs had been launched, 20% more new pharmaceuticals compared to the previous best in 1996. We are set to witness the explosive growth of AI-powered drugs in the coming years. Mentioned below are some of the biggest AI-powered drugs in the pharmaceutical industry right now.

Atom wise

The latest news about Atom wise is the formation of a strategic alliance with Charles River Laboratories International, Inc. This alliance provides customers with access to artificial intelligence (AI) based drug design technology. In mid-September, Atom wise entered into an evaluation agreement with Pfizer Inc. Pfizer will evaluate the Atom wise platform to identify potential drug candidates for up to three Pfizer selected target proteins. In the agreement, Pfizer will pay technology access fees and additional payments based on success for each target protein of interest. Atom wise will electronically analyze millions of different small molecules for each of Pfizer’s identified target proteins using its state-of-the-art AI platform to predict which ones can bind with high affinity to selected target proteins. Atom wise’s medical chemistry and computer science teams will also collaborate with Pfizer scientists.

Auransa

Auransa has signed an exclusive license agreement with China Oncology Focus Limited, a subsidiary of Lee’s Pharmaceutical Holdings, for AU018 rights in Greater China and Southeast Asia. As part of this agreement, Auransa will receive an upfront payment and will be eligible for milestone payments and sales royalties for the preclinical program identified by the company’s AI-powered SMARTTR ™ engine. In total, Auransa is eligible to receive up to $ 22.5 million after reaching milestones. China Oncology aims to obtain the right to develop and market a new cardioprotective agent for chemotherapy patients. AU018, currently in preclinical development, is a potentially best-in-class cardioprotective agent for chemotherapy in the treatment of cancer.

Cyclica

The company introduced Match Maker ™, a new in-depth proteome screening technology developed and validated over the last two years to identify DTIs. MatchMaker builds on Cyclica’s goal of combining protein, chemistry and genomics data and complementing them with high-performance computing and the development of cloud-supported algorithms. MatchMaker combines molecular biophysics and deep learning to predict the binding of new drug molecules to all proteins, for example, the cell. MatchMaker will drive the Company’s Ligand Express Protein Screening Platform, launching Differential Drug Design (DDD) for lead optimization and single target and multi-target drug design.

Exscientia

The company announced it raised $ 26 million in a series B round of financing. Exscientia will use proceeds from this funding to expand its stack-up drug discovery capability to significantly expand its portfolio of products, with the goal of building a broad portfolio of projects, internally and with partners, by the end of 2019. The round included the participation of new investors, Celgene Corporation, and an investor in health care, GT Healthcare Capital Partners, as well as the existing investor, Evotec AG. The company has made significant progress in 2018 and anticipates that its first AI-driven programs will be ready for IND in the next 12 months.

One of its most recent research interests is in intestinal bacteria and attempts to predict people’s biological age. To discover the evolution of the microbiome over time, Alex Zhavoronkov, a longevity researcher, and colleagues at InSilico Medicine, an Artificial Intelligence startup based in Rockville, Maryland, examined more than 3,600 samples of intestinal bacteria in 1165 healthy people living in the world. Zhavoronkov and his colleagues discovered that some microbes became more abundant as people aged. Changes in diet, sleep patterns and physical activity are likely to contribute to these bacterial species changes, says co-author Vadim Gladyshev, a Harvard University biologist who studies aging. According to Zhavoronkov, this microbiome aging clock could be used as a basis for testing the speed or slowness of a person’s intestinal aging and whether factors such as alcohol, antibiotics, probiotics or diet have an effect on longevity.

 

 

About Anand Sai 84 Articles
Anand Sai has worked in the field of market research as an analyst and a consultant and has also operated at several leadership positions. He has an enormous experience with respect to the compilation of high-quality market research reports and boasts over six years of experience in end-to-end project management. Anand is a dependable voice in the market research field and has been named in some of the top industry publications. He is also a travel junkie and loves to explore new places with his friends.